Evidence map›Paper›PMID 35763413›Full record

Trial reportThe Journal of infectious diseases2022

Population-Level Correlation Between Incidence of Curable Sexually Transmitted Infections and Human Immunodeficiency Virus (HIV)-1 Among African Women Participating in HIV-1 Pre-Exposure Prophylaxis Trials.

Portia Hunidzarira, Elizabeth R Brown, Z Mike Chirenje, Sharon L Hillier, Jeanne M Marrazzo, Thesla Palanee-Phillips, Flavia M Kiweewa, Jared M Baeten, MTN-003/VOICE and MTN-020/ASPIRE Study Teams

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Portia HunidzariraUniversity of Zimbabwe Clinical Trials Research Centre (UZ-CTRC), Harare, Zimbabwe.ORCID 0000-0001-6692-4378
Elizabeth R BrownFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Z Mike ChirenjeUniversity of Zimbabwe Clinical Trials Research Centre (UZ-CTRC), Harare, Zimbabwe.
Sharon L HillierMagee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
Jeanne M MarrazzoUniversity of Alabama at Birmingham, Department of Medicine, Division of Infectious Diseases, Birmingham, Alabama, USA.
Thesla Palanee-PhillipsUniversity of Washington, Department of Epidemiology; School of Public Health, Seattle, Washington, USA.
Flavia M KiweewaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Jared M BaetenUniversity of Washington, Department of Epidemiology; School of Public Health, Seattle, Washington, USA.
MTN-003/VOICE and MTN-020/ASPIRE Study Teams
University of Washington · USUniversity of Zimbabwe · ZWMUJHU Research Collaboration · UGUniversity of Alabama at Birmingham · USUniversity of Pittsburgh · USUniversity of the Witwatersrand · ZA

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

backgroundHighly efficacious oral pre-exposure prophylaxis (PrEP) is the global standard for human immunodeficiency virus (HIV)-1 prevention, including in clinical trials of novel PrEP agents using active-comparator designs. The analysis assessed whether incident sexually transmitted infections (STIs) can serve as a surrogate indicator of HIV-1 incidence that might occur in the absence of PrEP.

methodsWe analyzed data from 3256 women randomized to placebo groups of oral and vaginal PrEP trials (MTN-003/VOICE and MTN-020/ASPIRE). Regression modeling assessed the correlation between incident individual STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, each considered separately) and incident HIV-1.

resultsAcross 18 sites in 4 countries (Malawi, South Africa, Uganda, Zimbabwe), STI and HIV-1 incidences were high: HIV-1 4.9, N gonorrhoeae 5.3, C trachomatis 14.5, and T vaginalis 7.1 per 100 person-years. There was limited correlation between HIV-1 incidence and incidence of individual STIs: N gonorrhoeae (r = 0.02, P = .871), C trachomatis (r = 0.49, P = <.001), and T vaginalis (r = 0.10, P = .481). The modest association with C trachomatis was driven by country-level differences in both C trachomatis and HIV-1, with no statistically significant association within countries.

conclusionsSexually transmitted infection incidence did not reliably predict HIV-1 incidence at the population level among at-risk African women participating in 2 large PrEP trials.

Indexed as

Chlamydia InfectionsHIV-1HIV InfectionsPre-Exposure ProphylaxisSexually Transmitted DiseasesChlamydia trachomatisFemaleHumansIncidenceNeisseria gonorrhoeaePrevalenceclinical trial designHIV incidencesexually transmitted infectionswomen

Identifiers

PMID35763413
PMCPMC10233491
OpenAlexW4283640767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.